Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Pizzuti

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Biology Direct|June 23, 2025
Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic reviewEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
International Journal of Medical Sciences|April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS TrialEriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
Oncotarget|February 25, 2016
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Laura Pizzuti, Isabella Sperduti, et al.
NPJ Breast Cancer|May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo studyEriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
Nature Immunology|August 24, 2022
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1BMartina Musella, Andrea Guarracino, Nicoletta Manduca, et al.
Oncotarget|September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experiencePatrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
Journal of Cellular Physiology|January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidenceEriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Biology Direct|June 23, 2025
Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic reviewEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
International Journal of Medical Sciences|April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS TrialEriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
Oncotarget|February 25, 2016
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Laura Pizzuti, Isabella Sperduti, et al.
NPJ Breast Cancer|May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo studyEriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
Nature Immunology|August 24, 2022
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1BMartina Musella, Andrea Guarracino, Nicoletta Manduca, et al.
Oncotarget|September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experiencePatrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
Journal of Cellular Physiology|January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidenceEriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Pageof 12